Open AccessCaffeine citrate – Is it a silver bullet in neonatology?
Author(s) -
Bikash Shrestha,
Gaurav Jawa
Publication year - 2017
Publication title -
pediatrics and neonatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.569
H-Index - 36
eISSN - 2212-1692
pISSN - 1875-9572
DOI - 10.1016/j.pedneo.2016.10.003
Subject(s) - medicine , bronchopulmonary dysplasia , tolerability , apnea of prematurity , intensive care medicine , neonatology , adverse effect , apnea , drug , therapeutic index , caffeine , pharmacology , anesthesia , gestational age , pregnancy , genetics , biology
Caffeine citrate is one of the most prescribed drug in the present day NICU for apnea. Its efficacy, tolerability, wide therapeutic index and safety margin has made it the drug of choice among the methylxanthines. Its therapeutic uses in apnea of prematurity, mechanical ventilation, bronchopulmonary dysplasia has made it a "silver bullet" in neonatology. However, there are still controversies surrounding this drug. This review is aimed to update the reader about the basic pharmacology, current therapeutic uses, adverse effects, controversies as well as present and future research of caffeine.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom